• Home
• Products
  • UV Phototherapy
  • Derma 308
  • MED/MPD Tester
• Order
• FAQ
  • UV Phototherapy
  • Viedo
  • Instruction
  • Real stories
• Membership
• Contact
•  
• KERNEL
  • KERNEL Website
  • Colposcope
  • Photodynamic therapy
  • Patient monitor

Treatment of moderate to severe plaque psoriasis with concomitant efalizumab and narrow-band ultraviolet B phototherapy.

BACKGROUND:

Efalizumab therapy and narrow-band ultraviolet B (NB-UVB) phototherapy have different mechanisms of action; combined therapy may be more effective than either treatment alone in treating moderate to severe plaque psoriasis.

METHODS:

This study investigated the efficacy and safety of efalizumab (1 mg/kg/wk) combined with NB-UVB 3 times a week for 12 weeks, followed by efalizumab monotherapy for 12 additional weeks.

RESULTS:

Twenty patients were enrolled with mean Psoriasis Area and Severity Index (PASI) of 12.8 +/- 7.4, mean physician's global assessment (PGA) of 5 +/- 1, and mean body surface area (BSA) affected of 18.2% +/- 15.3% at baseline. At week 12, 65% of patients (n = 13) achieved PASI 75; mean PGA was 2 +/- 1, corresponding to a 60% reduction; and mean BSA was 4.7% +/- 4.1%, corresponding to a 74% reduction. The improvements seen at week 12 were maintained during the ensuing efalizumab monotherapy.

CONCLUSION:

Combination of efalizumab and NB-UVB followed by efalizumab monotherapy was effective and well tolerated, this warranting further investigation.

www.kerneluvb.com----The leader manufacturer of UV Phototherapy.